Hori­zon Phar­ma folds its cards on Friedre­ich’s Atax­ia af­ter Ac­tim­mune flunks PhI­II

A year-and-a-half af­ter launch­ing their Phase III study of their lead drug Ac­tim­mune for Friedre­ich’s Atax­ia, Hori­zon Phar­ma has had to call it quits af­ter rack­ing up a full slate of end­point fail­ures.

Not on­ly did the drug (in­ter­fer­on gam­ma-1b) flunk the pri­ma­ry on the mod­i­fied Friedre­ich’s Atax­ia Rat­ing Scale at 26 weeks com­pared to a place­bo, it al­so failed the sec­ondary guide posts as well. The Dublin-based com­pa­ny is now shut­ter­ing the pro­gram and walk­ing away.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER